IRVINE, CA / ACCESSWIRE / July 19, 2016 / Khang & Khang LLP (the "Firm") announces that a class action lawsuit has been filed against Endo International plc ("Endo" or the "Company") (NASDAQ: ENDP). Investors who purchased or otherwise acquired shares between March 2, 2015 and May 6, 2016 inclusive (the "Class Period"), are encouraged to contact the Firm prior to the July 25, 2016 lead plaintiff motion deadline.

If you purchased shares of Endo during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by email at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The complaint alleges that the Company failed to disclose: that Endo's arrangements with pharmacy benefit managers with respect to the migraine therapy, Frova, included questionable incentives intended to increase sales revenues; and as a result, Endo's revenues and revenue projections relied in part on unsustainable arrangements.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by email at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts:

KHANG & KHANG LLP
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang Khang LLP